359 related articles for article (PubMed ID: 7517172)
21. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
Bastion Y; Blay JY; Divine M; Brice P; Bordessoule D; Sebban C; Blanc M; Tilly H; Lederlin P; Deconinck E; Salles B; Dumontet C; Brière J; Coiffier B
J Clin Oncol; 1997 Aug; 15(8):2945-53. PubMed ID: 9256139
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.
Tilly H; Mounier N; Lederlin P; Brière J; Dupriez B; Sebban C; Bosly A; Biron P; Nouvel C; Herbrecht R; Bordessoule D; Coiffier B
J Clin Oncol; 2000 Mar; 18(6):1309-15. PubMed ID: 10715302
[TBL] [Abstract][Full Text] [Related]
23. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
[TBL] [Abstract][Full Text] [Related]
24. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
Oksenhendler E; Gerard L; Dubreuil ML; Levy Y; Matheron S; Cazals-Hatem D; Chevret S; Clauvel JP
Leuk Lymphoma; 2000 Sep; 39(1-2):87-95. PubMed ID: 10975387
[TBL] [Abstract][Full Text] [Related]
25. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Herbrecht R; Damonte JC; Dufour P; Maloisel F; Liu KL; Ortiz S; Bergerat JP; Oberling F
Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
[TBL] [Abstract][Full Text] [Related]
26. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.
Haioun C; Lepage E; Gisselbrecht C; Bastion Y; Coiffier B; Brice P; Bosly A; Dupriez B; Nouvel C; Tilly H; Lederlin P; Biron P; Brière J; Gaulard P; Reyes F
J Clin Oncol; 1997 Mar; 15(3):1131-7. PubMed ID: 9060555
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
[TBL] [Abstract][Full Text] [Related]
28. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
29. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
Linch DC; Smith P; Hancock BW; Hoskin PJ; Cunningham DC; Newland AC; Milligan D; Stevenson PA; Wood JK; Maclennan KA; Vaughan B; Vaughan G; Gregory WM
Ann Oncol; 2000; 11 Suppl 1():87-90. PubMed ID: 10707786
[TBL] [Abstract][Full Text] [Related]
30. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
Mounier N; Morel P; Haioun C; Coiffier B; Tilly H; Chatelain C; Lederlin P; Thyss A; Herbrecht R; Gisselbrecht C; Lepage E
Cancer; 1998 May; 82(10):1952-62. PubMed ID: 9587130
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.
Morel P; Gaulard P; Gisselbrecht C; Ferme C; Salles G; Tilly H; Brière J; Copin MC; Lederlin P; Hermine O; Theate I; Haioun C; Mounier N;
Ann Oncol; 2008 Mar; 19(3):560-5. PubMed ID: 18096567
[TBL] [Abstract][Full Text] [Related]
32. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
34. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Engelhard M; Brittinger G; Huhn D; Gerhartz HH; Meusers P; Siegert W; Thiel E; Wilmanns W; Aydemir U; Bierwolf S; Griesser H; Tiemann M; Lennert K
Blood; 1997 Apr; 89(7):2291-7. PubMed ID: 9116271
[TBL] [Abstract][Full Text] [Related]
35. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Cooper IA; Wolf MM; Robertson TI; Fox RM; Matthews JP; Stone JM; Ding JC; Dart G; Matthews J; Firkin FC
J Clin Oncol; 1994 Apr; 12(4):769-78. PubMed ID: 7512131
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
37. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584
[TBL] [Abstract][Full Text] [Related]
38. Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Waits TM; Greco FA; Greer JP; Hainsworth JD
Leuk Lymphoma; 1993 Aug; 10(6):453-9. PubMed ID: 7691308
[TBL] [Abstract][Full Text] [Related]
39. Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
Colombat P; Guilhot F; Bordesoule D; Renou P; Benz-Lemoine E; Fouillard L; Drouet M; Tanzer J; Lamagnere JP
Haematologica; 1991; 76(6):479-84. PubMed ID: 1726492
[TBL] [Abstract][Full Text] [Related]
40. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
